Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer

Contributed by: Business Wire

Tags

Pharmaceutical

Oncology

Health

Artificial Intelligence

Medical Devices

Technology

Clinical Trials

Other Health

myStage Dx

More Like This

New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX® Test on Patient Care and Healthcare Efficiency

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

PR Newswire associated0

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

HER2DX studies presented at ASCO.

ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients

Groundbreaking Study Confirms Clinical Decision Impact of HER2DX® Genomic Assay in Early-Stage HER2-Positive Breast Cancer